MY125564A - Combination therapy for treatment of psychoses - Google Patents

Combination therapy for treatment of psychoses

Info

Publication number
MY125564A
MY125564A MYPI97004299A MYPI9704299A MY125564A MY 125564 A MY125564 A MY 125564A MY PI97004299 A MYPI97004299 A MY PI97004299A MY PI9704299 A MYPI9704299 A MY PI9704299A MY 125564 A MY125564 A MY 125564A
Authority
MY
Malaysia
Prior art keywords
psychoses
treatment
combination therapy
combination
olanzapine
Prior art date
Application number
MYPI97004299A
Other languages
English (en)
Inventor
Franklin Porter Bymaster
Kenneth Wayne Perry
Gary Dennis Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MY125564A publication Critical patent/MY125564A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MYPI97004299A 1996-09-23 1997-09-16 Combination therapy for treatment of psychoses MY125564A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2688496P 1996-09-23 1996-09-23

Publications (1)

Publication Number Publication Date
MY125564A true MY125564A (en) 2006-08-30

Family

ID=21834363

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97004299A MY125564A (en) 1996-09-23 1997-09-16 Combination therapy for treatment of psychoses

Country Status (29)

Country Link
US (1) US6147072A (enExample)
EP (1) EP0830864B9 (enExample)
JP (1) JP2001503031A (enExample)
KR (1) KR100532901B1 (enExample)
CN (1) CN1162156C (enExample)
AR (1) AR008462A1 (enExample)
AT (1) ATE231724T1 (enExample)
AU (1) AU719033C (enExample)
BR (1) BR9711530A (enExample)
CA (1) CA2264941C (enExample)
CO (1) CO4900058A1 (enExample)
CZ (1) CZ301154B6 (enExample)
DE (1) DE69718731T2 (enExample)
DK (1) DK0830864T3 (enExample)
EA (1) EA001317B1 (enExample)
EG (1) EG24660A (enExample)
ES (1) ES2191152T3 (enExample)
HU (1) HU228178B1 (enExample)
IL (2) IL161833A0 (enExample)
MY (1) MY125564A (enExample)
NO (1) NO319166B1 (enExample)
NZ (1) NZ334168A (enExample)
PE (1) PE110198A1 (enExample)
PL (1) PL190374B1 (enExample)
RS (1) RS49828B (enExample)
TW (1) TW541178B (enExample)
UA (1) UA62937C2 (enExample)
WO (1) WO1998011897A1 (enExample)
ZA (1) ZA977967B (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
DK1071425T3 (da) * 1998-04-24 2007-12-27 Scarista Ltd Behandling af depression og farmaceutiske præparater dertil
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
UA78181C2 (en) * 1998-05-22 2007-03-15 Lilly Co Eli Combined therapy for treating refractory depressive states
SK17492000A3 (sk) * 1998-05-29 2002-04-04 Eli Lilly And Company Liek na liečenie bipolárnych porúch a farmaceutický prostriedok
AU1321900A (en) * 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
EP1133299A1 (en) * 1998-11-23 2001-09-19 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1161241B1 (de) 1999-03-12 2005-12-07 Aesica Pharmaceuticals Ltd. Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
AU4552200A (en) * 1999-05-12 2000-12-05 Solvay Pharmaceuticals B.V. Method of treating psychotic disorders
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
AU4973800A (en) * 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
EP1220658A1 (en) * 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
US6476051B2 (en) 1999-12-17 2002-11-05 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
CZ20022047A3 (cs) 1999-12-23 2003-09-17 Pfizer Products Inc. Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
WO2002003684A2 (en) * 2000-06-30 2002-01-10 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
JP2004517112A (ja) 2001-01-02 2004-06-10 ファルマシア・アンド・アップジョン・カンパニー 新規薬物コンビネーション
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CN1509169A (zh) * 2001-05-01 2004-06-30 H��¡�±������޹�˾ 对映体纯艾司西酞普兰的用途
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
MXPA05000294A (es) * 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AU2004308413A1 (en) * 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
WO2005070332A1 (en) * 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006027800A1 (en) * 2004-09-06 2006-03-16 Shasun Chemicals And Drugs Limited A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
EP1830844A1 (en) * 2004-12-27 2007-09-12 Alpha 2 Pharmaceutical AB Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US20070093471A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals, Llc Compositions and methods for the administration clozapine formulations which modulate body weight
CA2677623C (en) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
RU2508106C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2508096C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
MY157192A (en) * 2007-08-03 2016-05-13 Richter Gedeon Nyrt Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
CN101939004A (zh) * 2008-01-25 2011-01-05 阿尔法制药有限公司 度洛西汀的缓释药物组合物
WO2011018801A2 (en) * 2009-08-12 2011-02-17 Genepharm India Pvt Ltd Solid oral dosage form of ziprasidone
EP2496079A4 (en) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AU2014361813A1 (en) * 2013-12-13 2016-07-28 Ralph ANKENMAN Compositions and methods for treating dysregulated systems
US9782398B2 (en) * 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
CN108938635A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种低剂量非典型抗精神病药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
US5846928A (en) * 1996-08-01 1998-12-08 Pasken Products Co., Ltd. Method for treating cancer patients
US5877198A (en) * 1996-10-17 1999-03-02 Milkhaus Laboratory, Inc. Treatment of urinary incontinence

Also Published As

Publication number Publication date
AU4411297A (en) 1998-04-14
DE69718731D1 (de) 2003-03-06
NZ334168A (en) 2000-09-29
CN1230886A (zh) 1999-10-06
US6147072A (en) 2000-11-14
CZ301154B6 (cs) 2009-11-18
EA199900324A1 (ru) 1999-08-26
PE110198A1 (es) 1999-01-21
PL190374B1 (pl) 2005-12-30
KR100532901B1 (ko) 2005-12-02
ATE231724T1 (de) 2003-02-15
HU228178B1 (en) 2013-01-28
HUP9903905A2 (hu) 2000-10-28
YU15299A (sh) 2002-06-19
PL332481A1 (en) 1999-09-13
CZ98799A3 (cs) 1999-12-15
HK1009755A1 (en) 1999-06-11
RS49828B (sr) 2008-08-07
IL128730A0 (en) 2000-01-31
NO991381L (no) 1999-03-22
CN1162156C (zh) 2004-08-18
KR20000048518A (ko) 2000-07-25
NO991381D0 (no) 1999-03-22
JP2001503031A (ja) 2001-03-06
EP0830864B1 (en) 2003-01-29
WO1998011897A1 (en) 1998-03-26
TW541178B (en) 2003-07-11
AU719033C (en) 2005-08-04
BR9711530A (pt) 1999-08-24
CA2264941A1 (en) 1998-03-26
NO319166B1 (no) 2005-06-27
DE69718731T2 (de) 2003-09-11
ZA977967B (en) 1999-03-04
CA2264941C (en) 2008-11-18
UA62937C2 (uk) 2004-01-15
EP0830864A1 (en) 1998-03-25
CO4900058A1 (es) 2000-03-27
EA001317B1 (ru) 2001-02-26
AR008462A1 (es) 2000-01-19
EP0830864B9 (en) 2003-09-03
IL161833A0 (en) 2005-11-20
ES2191152T3 (es) 2003-09-01
AU719033B2 (en) 2000-05-04
EG24660A (en) 2010-04-07
HUP9903905A3 (en) 2001-03-28
DK0830864T3 (da) 2003-05-26

Similar Documents

Publication Publication Date Title
MY125564A (en) Combination therapy for treatment of psychoses
UA32429C2 (uk) Засіб для лікування нетримання сечі
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
GB9818916D0 (en) Use
PH31335A (en) Naphthalamides as central nervous system agent.
ZA200204416B (en) Carbon dioxide enhancement of inhalation therapy.
IL139591A0 (en) Combination therapy for treatment of bipolar disorders
FI964341L (fi) Prosessi ja laitteisto, joilla vähennetään kehon tietyissä kohdissa olevaa rasvakudosta yhdistetyllä lämpökäsittelyllä ja lihastoiminnalla
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
GB0020504D0 (en) Therapeutic method
MX9805064A (es) Uso de 2-metil-4-(4-metil-1-piperazinil)-1oh-tieno[2,3-b][1,5]benzo diazepina.
NZ332037A (en) Olanzapine for treating migraine pain
PL344574A1 (en) Cabergoline and pramipexole: new uses and combinations
PL356001A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
MY124071A (en) Treatment of viral disease in swine
NZ324615A (en) Method for treating autism using olanzapine
PT1212119E (pt) Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas
IL126158A0 (en) Method for treating substance abuse
IL143279A0 (en) Novel therapeutic application of low molecular weight heparin
ES2185777T3 (es) Tratamiento de la anorexia.
EA199800818A1 (ru) Способ лечения бессонницы
IL126157A0 (en) Method for treating excessive aggression
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії
UA36261A (uk) Спосіб лікування простої шизофренії з суїцидальною поведінкою